236 related articles for article (PubMed ID: 31930696)
1. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
[TBL] [Abstract][Full Text] [Related]
2. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
[TBL] [Abstract][Full Text] [Related]
4. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
5. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
7. Topical sirolimus for treatment of a venolymphatic malformation in an adolescent girl.
Cardis MA; DeKlotz CMC
Pediatr Dermatol; 2018 Nov; 35(6):e406-e407. PubMed ID: 30152558
[TBL] [Abstract][Full Text] [Related]
8. Use of topical rapamycin in the treatment of superficial lymphatic malformations.
García-Montero P; Del Boz J; Baselga-Torres E; Azaña-Defez JM; Alcaraz-Vera M; Tercedor-Sánchez J; Noguera-Morel L; Vera-Casaño Á
J Am Acad Dermatol; 2019 Feb; 80(2):508-515. PubMed ID: 30296533
[TBL] [Abstract][Full Text] [Related]
9. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
Sandbank S; Molho-Pessach V; Farkas A; Barzilai A; Greenberger S
Acta Derm Venereol; 2019 Oct; 99(11):990-996. PubMed ID: 31304557
[TBL] [Abstract][Full Text] [Related]
10. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
[TBL] [Abstract][Full Text] [Related]
11. Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations.
Triana P; Miguel M; Díaz M; Cabrera M; López Gutiérrez JC
Lymphat Res Biol; 2019 Oct; 17(5):504-511. PubMed ID: 30985248
[No Abstract] [Full Text] [Related]
12. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants.
Czechowicz JA; Long-Boyle JR; Rosbe KW; Mathes EF; Frieden IJ; Shimano KA
Int J Pediatr Otorhinolaryngol; 2018 Feb; 105():48-51. PubMed ID: 29447818
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Topical Sirolimus (Rapamycin) for the Treatment of Microcystic Lymphatic Malformations.
Ivars M; Redondo P
JAMA Dermatol; 2017 Jan; 153(1):103-105. PubMed ID: 27784048
[No Abstract] [Full Text] [Related]
14. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus for the treatment of complicated vascular anomalies in children.
Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
[TBL] [Abstract][Full Text] [Related]
18. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.
Durand R; Reid JR; Belasco JB; Shellikeri S; Calle-Toro JS; Cahill AM; Srinivasan A
AJR Am J Roentgenol; 2021 Sep; 217(3):741-752. PubMed ID: 33405944
[No Abstract] [Full Text] [Related]
19. Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus.
Dvorakova V; Rea D; O'Regan GM; Irvine AD
Pediatr Dermatol; 2018 Jul; 35(4):533-534. PubMed ID: 29582448
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.
Ricci KW; Hammill AM; Mobberley-Schuman P; Nelson SC; Blatt J; Bender JLG; McCuaig CC; Synakiewicz A; Frieden IJ; Adams DM
Pediatr Blood Cancer; 2019 May; 66(5):e27614. PubMed ID: 30672136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
